PMID: 3755647Oct 1, 1986Paper

Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy

Cancer
P ValagussaG Bonadonna

Abstract

The efficacy of salvage treatments in 243 patients with operable breast cancer and positive axillary nodes who failed during or after adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and fluorouracil) was analyzed. Results were compared with those achieved in 100 patients who had relapses after radical mastectomy alone (control group). Salvage treatments consisted primarily of endocrine therapy (castration in premenopausal patients and tamoxifen in postmenopausal women) and chemotherapy (CMF or Adriamycin [doxorubicin] regimens). In 20 patients, however, first salvage treatment consisted of local therapy only (i.e., radiation therapy with or without surgery). In women previously treated with adjuvant CMF, complete plus partial remissions after first salvage treatment were 37% with a median duration of 17 months. In the control group, the response rate was 43% with a median duration of 16 months. The findings also indicated that drug-induced amenorrhea did not lower the objective response to salvage castration. In patients failing with a disease-free interval in excess of 12 months from end of adjuvant CMF, retreatment with the same combination was able to induce remission in 52% of the patients. Current data, deri...Continue Reading

References

Feb 19, 1976·The New England Journal of Medicine·G BonadonnaU Veronesi
Apr 3, 1976·British Medical Journal·C BrambillaG Bonadonna
Jan 1, 1985·Breast Cancer Research and Treatment·G BonadonnaU Veronesi
Feb 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Bonadonna, P Valagussa
Mar 1, 1983·International Journal of Radiation Oncology, Biology, Physics·G Bonadonna, P Valagussa
Jan 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G TanciniU Veronesi
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, H Bush
Aug 9, 1984·The New England Journal of Medicine
Jan 1, 1981·The New England Journal of Medicine·G Bonadonna, P Valagussa

❮ Previous
Next ❯

Citations

Jan 1, 1994·World Journal of Surgery·K Wong, I C Henderson
Jan 1, 1990·Breast Cancer Research and Treatment·J RouesseM Brunet
Apr 15, 2005·Breast Cancer Research and Treatment·Sun Young RhaHyun Cheol Chung
Jun 9, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Castiglione-GertschC M Rudenstam
Mar 22, 2002·The Lancet Oncology·A J Davis, J F Tannock
May 23, 2001·Breast Cancer Research and Treatment·E AlbaJ Miramón
Jan 1, 1993·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·L Norton
Dec 29, 2015·Breast Cancer Research and Treatment·Otto Metzger-FilhoUNKNOWN HREA Study Team
May 22, 2007·Hematology/oncology Clinics of North America·Erica L Mayer, Harold J Burstein
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J HoustonR D Rubens
Apr 1, 1993·Cancer Treatment Reviews·P G de TakatsJ M Morrison
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R D RubensR Paridaens
Jan 1, 1995·Clinical Oncology : a Journal of the Royal College of Radiologists·D BissettS Kaye
May 1, 1989·The American Journal of Hospice Care·R J Miller
Nov 30, 1993·Annals of the New York Academy of Sciences·A Surbone, L Norton
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P AcklandUNKNOWN HEPI 013 study group
Mar 16, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Cara, I F Tannock

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.